Type 5 17beta-hydroxysteroid Dehydrogenase/prostaglandin F Synthase (AKR1C3): Role in Breast Cancer and Inhibition by Non-steroidal Anti-inflammatory Drug Analogs

Overview

Journal Chem Biol Interact

Publisher Elsevier

Specialties Biochemistry
Molecular Biology
Pharmacology

Date 2008 Nov 18

PMID 19010312

Citations 26

Authors

Michael C Byrns

Trevor M Penning

Affiliations

Soon will be listed here.

Abstract

Aldo-keto reductase (AKR) 1C3 catalyzes the NADPH-dependent reduction of Delta(4)-androstene-3,17-dione to yield testosterone, reduction of estrone to yield 17beta-estradiol and reduction of progesterone to yield 20alpha-hydroxyprogesterone. In addition, it functions as a prostaglandin (PG) F synthase and reduces PGH(2) to PGF(2)alpha and PGD(2) to 11beta-PGF(2). Immunohistochemistry showed that AKR1C3 is over-expressed in invasive ductal carcinoma of the breast. Retroviral expression of AKR1C3 in MCF-7 breast carcinoma cells shows that each of the assigned reactions occur in a breast cell microenvironment. Steroid and prostaglandin conversions were monitored by radiochromatography. Prostaglandin conversion was validated by a second method using HPLC coupled to APCI-MRM/MS. The combined effect of the AKR1C3 catalyzed 17- and 20-ketosteroid reductions will be to increase the 17beta-estradiol:progesterone ratio in the breast. In addition, formation of PGF(2) epimers would activate F prostanoid receptors and deprive PPARgamma of its putative anti-proliferative PGJ(2) ligands. Thus, AKR1C3 is a source of proliferative signals and a potential therapeutic target for hormone-dependent and -independent breast cancer. Two strategies for AKR1C3 inhibition based on non-steroidal anti-inflammatory drugs were developed. The first strategy uses the Ullmann coupling reaction to generate N-phenylanthranilate derivatives that inhibit AKR1C enzymes without affecting PGH(2) synthase (PGHS) 1 or PGHS-2. The second strategy exploits the selective inhibition of AKR1C3 by indomethacin, which did not inhibit highly related AKR1C1 or AKR1C2. Using known structure-activity relationships for the inhibition of PGHS-1 and PGHS-2 by indole acetic acids we obtained N-(4-chlorobenzoyl)-melatonin as a specific AKR1C3 inhibitor (K(I)=6.0muM) that does not inhibit PGHS-1, PGHS-2, AKR1C1, or AKR1C2. Both strategies are informed by crystal structures of ternary AKR1C3.NADP(+).NSAID complexes. The identification of NSAID analogs as specific inhibitors of AKR1C3 will help validate its role in the proliferation of breast cancer cells.

Citing Articles

AKR1C3 mediates gastric cancer cell invasion and metastasis via the AKT and JNK/p-NF-κB signaling pathways.

Lin L, Xiao X, Guo X, Zhong C, Zhuang M, Xu J Sci Rep. 2024; 14(1):30263.

PMID: 39632995 PMC: 11618362. DOI: 10.1038/s41598-024-82039-w.

AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies.

Li M, Zhang L, Yu J, Wang X, Cheng L, Ma Z Front Pharmacol. 2024; 15:1378292.

PMID: 38523637 PMC: 10957692. DOI: 10.3389/fphar.2024.1378292.

Role of Human Aldo-Keto Reductases and Nuclear Factor Erythroid 2-Related Factor 2 in the Metabolic Activation of 1-Nitropyrene via Nitroreduction in Human Lung Cells.

Su A, Penning T Chem Res Toxicol. 2023; 36(2):270-280.

PMID: 36693016 PMC: 9974908. DOI: 10.1021/acs.chemrestox.2c00337.

The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting.

Walker O, Dahn M, Power Coombs M, Marcato P Front Oncol. 2022; 11:791696.

PMID: 35127497 PMC: 8807694. DOI: 10.3389/fonc.2021.791696.

Influence of Indomethacin on Steroid Metabolism: Endocrine Disruption and Confounding Effects in Urinary Steroid Profiling of Anti-Doping Analyses.

Stoll A, Iannone M, De Gregorio G, Molaioni F, de la Torre X, Botre F Metabolites. 2020; 10(11).

PMID: 33202527 PMC: 7698016. DOI: 10.3390/metabo10110463.

References

Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N . Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer. 2005; 12(4):701-20. DOI: 10.1677/erc.1.00834. View

Jansson A, Gunnarsson C, Cohen M, Sivik T, Stal O . 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res. 2006; 66(23):11471-7. DOI: 10.1158/0008-5472.CAN-06-1448. View

Byrns M, Steckelbroeck S, Penning T . An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone.... Biochem Pharmacol. 2007; 75(2):484-93. PMC: 2245880. DOI: 10.1016/j.bcp.2007.09.008. View

Sharma K, Lindqvist A, Zhou X, Auchus R, Penning T, Andersson S . Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol Cell Endocrinol. 2005; 248(1-2):79-86. DOI: 10.1016/j.mce.2005.10.024. View

Kalgutkar A, Crews B, Saleh S, Prudhomme D, Marnett L . Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. Bioorg Med Chem. 2005; 13(24):6810-22. DOI: 10.1016/j.bmc.2005.07.073. View

Kalgutkar A, Marnett A, Crews B, Remmel R, Marnett L . Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem. 2000; 43(15):2860-70. DOI: 10.1021/jm000004e. View

Matsuura K, Shiraishi H, Hara A, Sato K, Deyashiki Y, Ninomiya M . Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem. 1998; 124(5):940-6. DOI: 10.1093/oxfordjournals.jbchem.a022211. View

Dhagat U, Carbone V, Chung R, Matsunaga T, Endo S, Hara A . A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase. Med Chem. 2007; 3(6):546-50. DOI: 10.2174/157340607782360399. View

Prusakiewicz J, Felts A, Mackenzie B, Marnett L . Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin. Biochemistry. 2004; 43(49):15439-45. DOI: 10.1021/bi048534q. View

10.

Lin H, Steckelbroeck S, Fung K, Jones A, Penning T . Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids. 2004; 69(13-14):795-801. DOI: 10.1016/j.steroids.2004.09.014. View

11.

Oduwole O, Li Y, Isomaa V, Mantyniemi A, Pulkka A, Soini Y . 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res. 2004; 64(20):7604-9. DOI: 10.1158/0008-5472.CAN-04-0446. View

12.

Shiraki T, Kamiya N, Shiki S, Kodama T, Kakizuka A, Jingami H . Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma. J Biol Chem. 2005; 280(14):14145-53. DOI: 10.1074/jbc.M500901200. View

13.

Kim H, Kim J, Meng Z, Wang L, Liu F, Conrads T . 15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain. Cancer Res. 2007; 67(6):2595-602. DOI: 10.1158/0008-5472.CAN-06-3043. View

14.

Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K . Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer. 2008; 15(1):113-24. DOI: 10.1677/ERC-07-0092. View

15.

Penning T, Talalay P . Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins. Proc Natl Acad Sci U S A. 1983; 80(14):4504-8. PMC: 384067. DOI: 10.1073/pnas.80.14.4504. View

16.

Lovering A, Ride J, Bunce C, Desmond J, Cummings S, White S . Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res. 2004; 64(5):1802-10. DOI: 10.1158/0008-5472.can-03-2847. View

17.

Penning T, Burczynski M, Jez J, Hung C, Lin H, Ma H . Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J. 2000; 351(Pt 1):67-77. PMC: 1221336. DOI: 10.1042/0264-6021:3510067. View

18.

Carnevale R, Proietti C, Salatino M, Urtreger A, Peluffo G, Edwards D . Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol. 2007; 21(6):1335-58. DOI: 10.1210/me.2006-0304. View

19.

Kalgutkar A, Crews B, Rowlinson S, Marnett A, Kozak K, Remmel R . Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000; 97(2):925-30. PMC: 15432. DOI: 10.1073/pnas.97.2.925. View

20.

Bauman D, Steckelbroeck S, Penning T . The roles of aldo-keto reductases in steroid hormone action. Drug News Perspect. 2005; 17(9):563-78. DOI: 10.1358/dnp.2004.17.9.872570. View